Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
BNP may refine mortality prediction beyond ANP in chronic CHF; leaves open its role in contemporary risk models.
These findings indicate that plasma BNP is more useful than ANP for assessing the mortality in patients with chronic CHF and that the plasma levels of BNP provide prognostic information independent of other variables previously associated with a poor prognosis. Our findings also suggest that the compensatory activity of the cardiac natriuretic peptide system is attenuated as mortality increases in chronic CHF patients with high plasma levels of ANP and BNP.
No takes yet. Share an insight, caveat, or question.
Tsutamoto et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: